| 04/30/2026 11:05 AM | Bulto Carulla Victor (2098937) Reporting Novartis (1114448) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/28/2026 5:21 AM | Novartis (1114448) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 03/18/2026 3:23 PM | Novartis (1114448) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 03/17/2026 3:40 PM | Novartis (1114448) Filer Novartis Capital CORP (1443411) Filer | Form 424B5 | |
| 03/16/2026 7:16 AM | Novartis (1114448) Filer Novartis Capital CORP (1443411) Filer | Form 424B5 | |
| 02/12/2026 1:43 PM | Marshall Fiona (2070012) Reporting Novartis (1114448) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 02/09/2026 10:49 AM | Bulto Carulla Victor (2098937) Reporting Novartis (1114448) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 02/04/2026 3:30 PM | Novartis (1114448) Filer | Form S-8 Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
| 02/04/2026 5:45 AM | Novartis (1114448) Filer | Form 20-F Registration statement / Annual report / Transition report | |
| 02/04/2026 5:50 AM | Novartis (1114448) Filer | Form IRANNOTICE | |
| 02/04/2026 5:51 AM | Novartis (1114448) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
Get the Latest News and Ratings for NVS and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Novartis and its competitors with MarketBeat's FREE daily newsletter.
|
| 02/04/2026 5:52 AM | Novartis (1114448) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 01/14/2026 3:01 PM | Avidity Biosciences, Inc. (1599901) Subject Novartis (1114448) Filed by | Form DFAN14A | |
| 01/12/2026 3:35 PM | Avidity Biosciences, Inc. (1599901) Subject Novartis (1114448) Filed by | Form DFAN14A | |
| 11/20/2025 5:05 AM | Novartis (1114448) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 11/05/2025 3:33 PM | Novartis (1114448) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 11/04/2025 3:43 PM | Novartis (1114448) Filer Novartis Capital CORP (1443411) Filer | Form 424B5 | |
| 11/03/2025 7:59 PM | Novartis (1114448) Subject | Form FWP | |
| 11/03/2025 7:08 AM | Novartis (1114448) Filer Novartis Capital CORP (1443411) Filer | Form 424B5 | |
| 10/28/2025 4:26 PM | Avidity Biosciences, Inc. (1599901) Subject Novartis (1114448) Filed by | Form DFAN14A | |
| 10/28/2025 11:12 AM | Novartis (1114448) Reporting Tourmaline Bio, Inc. (1827506) Issuer Tourmaline Bio, Inc. (1827506) Issuer | Form 3 Initial statement of beneficial ownership of securities | |
| 10/28/2025 9:08 AM | Novartis (1114448) Filed by Tourmaline Bio, Inc. (1827506) Subject Tourmaline Bio, Inc. (1827506) Subject | Form SC TO-T/A | |
| 10/28/2025 6:00 AM | Avidity Biosciences, Inc. (1599901) Subject Novartis (1114448) Filed by | Form DFAN14A | |
| 10/28/2025 5:07 AM | Novartis (1114448) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 10/27/2025 4:14 PM | Avidity Biosciences, Inc. (1599901) Subject Novartis (1114448) Filed by | Form DFAN14A | |
| 10/27/2025 5:31 AM | Avidity Biosciences, Inc. (1599901) Subject Novartis (1114448) Filed by | Form DFAN14A | |
| 10/27/2025 5:12 AM | Avidity Biosciences, Inc. (1599901) Subject Novartis (1114448) Filed by | Form DFAN14A | |
| 10/27/2025 5:06 AM | Novartis (1114448) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 10/22/2025 7:06 AM | Novartis (1114448) Filed by Tourmaline Bio, Inc. (1827506) Subject Tourmaline Bio, Inc. (1827506) Subject | Form SC TO-T/A | |
| 10/20/2025 7:36 AM | Novartis (1114448) Filed by Tourmaline Bio, Inc. (1827506) Subject Tourmaline Bio, Inc. (1827506) Subject | Form SC TO-T/A | |
| 09/30/2025 4:12 PM | Novartis (1114448) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 09/29/2025 5:53 AM | Novartis (1114448) Filed by Tourmaline Bio, Inc. (1827506) Subject Tourmaline Bio, Inc. (1827506) Subject | Form SC TO-T | |
| 07/17/2025 3:15 PM | Novartis (1114448) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 07/17/2025 6:16 AM | Novartis (1114448) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 06/25/2025 8:24 AM | Novartis (1114448) Filed by Regulus Therapeutics Inc. (1505512) Subject | Form SC TO-T/A | |
| 06/23/2025 5:02 AM | Novartis (1114448) Filed by Regulus Therapeutics Inc. (1505512) Subject | Form SC TO-T/A | |
| 06/17/2025 5:30 AM | Novartis (1114448) Filed by Regulus Therapeutics Inc. (1505512) Subject | Form SC TO-T/A | |
| 06/02/2025 5:05 AM | Novartis (1114448) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/27/2025 5:56 AM | Novartis (1114448) Filed by Regulus Therapeutics Inc. (1505512) Subject | Form SC TO-T | |